top of page

2025 - 2.png

MEDIA GALLERY

Sessions, replayed

Case-based reviews, panel discussions and trial-design panels, recorded in full.

DAY 1

NextGen IgA Nephropathy Trials

Clinical Trial Design

DAY 2

C3 Glomerulopathy

Case-based

DAY 2

Apol1-mediated Kidney Disease

Case-based

DAY 3

Trial Design in Primary FSGS

Clinical Trial Design

VIDEO

Session recordings

Day 1 · Late breaking clinical trial

Sibeprenlimab in IgA Nephropathy: Topline 24-Month eGFR Results

New data from the Phase 3 VISIONARY trial demonstrate that VOYXACT (sibeprenlimab-szsi) stabilizes eGFR, returning the rate of kidney function decline to the baseline physiologic rate over two years in adults with primary IgA nephropathy (IgAN) at risk for disease progression.

DAY 3

Immunosuppression & Risk Management

Clinical Practice Points

DAY 4

Membranous
Nephropathy

Case-based

DAY 4

Digital Twins in Nephrology Clinical Trials

Clinical Trial Design

DAY 5

ANCA
Glomerulonephritis

Case-based

DAY 5

The Outcasts - A roundtable discussion

Clinical Trial Design

DAY 5

Paraprotein-mediated Kidney Disease

Case-based

WATCH ALL VIDEOS IN YOUTUBE

PHOTOGRAPHY

Conference gallery

VIEW ALL PHOTOS

REGISTER

Join us in GlomCon Hawaii 2027

GlomCon Hawaii 2027 · September 27–30, 2027 · Grand Wailea Maui. Hybrid attendance available worldwide.

bottom of page